US trumps Europe in public funding for cancer research

July 17, 2006

A major pan-European survey published in PLoS Medicine has found that there is inadequate public funding of cancer research relative to the actual burden of cancer in Europe.

The European Cancer Research Funding Survey found that across the entire European Union, the average public spending on cancer research was only 2.56 Euros (US$3.30) per person, compared with 17.63 Euros (US$22.76) per person in the United States. As a percentage of GDP, the US spent four times as much as the average across the entire European survey.

The survey authors, Seth Eckhouse (Chief Project Officer, European Cancer Research Managers Forum) and Richard Sullivan (Director, Clinical Programmes and Centres, Cancer Research UK), say that public funding for cancer research--from governments, charities, and European organizations--is crucially important for reducing the cancer burden. "This funding," they say, "focused on the needs of patients with cancer rather than the commercial or economic advantage, is essential to deliver the myriad of solutions that cancer demands, from new strategies to prevent cancer, to therapies and improvements in patients' quality of life."
-end-
Citation: Eckhouse S, Sullivan R (2006) A survey of public funding of cancer research in the European Union. PLoS Med 3(7): e267.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030267

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-07-sullivan.pdf

Related images for press use: http://www.plos.org/press/plme-03-07-sullivan.jpg

Caption: Comparison of direct cancer research spend between EU-15 only and the United States of America as percentage of GDP

CONTACT:

Richard Sullivan
Cancer Research UK
Clinical & Translational Research Directorate
61 Lincoln's Inn Fields
London, London WC2A 3PX
United Kingdom
+44 2070616053
Richard.Sullivan@cancer.org.uk

Please mention the open-access journal plos medicine (www.plosmedicine.org) as the source for these articles and provide a link to the freely-available text. thank you.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

PLOS

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.